Effect of ischemic postconditioning during primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction: A randomized clinical trial

JAMA Cardiology

Volumn 2, Issue 5, 2017, Pages 490-497

  Engstrøm, Thomas ^a   Kelbæk, Henning ^b   Helqvist, Steffen ^a   Høfsten, Dan Eik ^a   Kløvgaard, Lene ^a   Clemmensen, Peter ^a   Holmvang, Lene ^a   Jørgensen, Erik ^a   Pedersen, Frants ^a   Saunamaki, Kari ^a   Ravkilde, Jan ^c   Tilsted, Hans Henrik ^a   Villadsen, Anton ^c   Aarøe, Jens ^c   Jensen, Svend Eggert ^c   Raungaard, Bent ^c   Bøtker, Hans E ^d   Terkelsen, Christian J ^d   Maeng, Michael ^d   Kaltoft, Anne ^d   Krusell, Lars R ^d   Jensen, Lisette O ^e   Veien, Karsten T ^e   Kofoed, Klaus Fuglsang ^a   Torp Pedersen, Christian ^c   Kyhl, Kasper ^a   Nepper Christensen, Lars ^a   Treiman, Marek ^f   Vejlstrup, Niels ^a   Ahtarovski, Kiril ^a   Lønborg, Jacob ^a   Køber, Lars ^a   Thygesen, Kristian ^d   Jeppesen, Jørgen ^g   Galløe, Anders ^b   Jensen, Gorm Boje ^h   Gislasson, Gunnar ⁱ   Erlinge, David ^j   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^h HVIDOVRE HOSPITAL   (Denmark)

ⁱ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^j LUND UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIVALIRUDIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL SUCCINATE; PRASUGREL; TICAGRELOR;

ADULT; ALL CAUSE MORTALITY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL OUTCOME; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY STENTING; DENMARK; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; ISCHEMIC POSTCONDITIONING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT FAILURE; AGED; CARDIAC MUSCLE; CAUSE OF DEATH; CORONARY BLOOD VESSEL; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; STENT; TREATMENT OUTCOME;

AGED; CAUSE OF DEATH; CORONARY VESSELS; DENMARK; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; ISCHEMIC POSTCONDITIONING; MALE; MIDDLE AGED; MORTALITY; MYOCARDIUM; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; ST ELEVATION MYOCARDIAL INFARCTION; STENTS; TREATMENT OUTCOME;

EID: 85026826837     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.0022     Document Type: Article

References (35)

1. Windecker S, Kolh P, Alfonso F, et al; Authors/Task Force members. 2014 ESC/EACTS guidelines onmyocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11): 1121-1135.
3. Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA. 2005;293(8):979-986.
4. Lonborg J, Kelbak H, Vejlstrup N, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv. 2010;3 (1):34-41.
5. Sun H, Guo T, Liu L, et al. Ischemic postconditioning inhibits apoptosis after acute myocardial infarction in pigs. Heart Surg Forum. 2010;13(5):E305-E310.
6. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition ofmyocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285(2):H579-H588.
7. Mykytenko J, Reeves JG, Kin H, et al. Persistent beneficial effect of postconditioning against infarct size: role of mitochondrial K(ATP) channels during reperfusion. Basic Res Cardiol. 2008;103(5):472-484.
8. Lonborg JT. Targeting reperfusion injury in the era of primary percutaneous coronary intervention: hope or hype? Heart. 2015;101(20):1612-1618.
9. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. 2005;112(14): 2143-2148.
10. Thibault H, Piot C, Ovize M. Postconditioning in man. Heart Fail Rev. 2007;12(3-4):245-248.
11. Xue F, Yang X, Zhang B, et al. Postconditioning the human heart in percutaneous coronary intervention. Clin Cardiol. 2010;33(7):439-444.
12. Sorensson P, Saleh N, Bouvier F, et al. Effect of postconditioning on infarct size in patients with ST elevationmyocardial infarction. Heart. 2010;96(21): 1710-1715.
13. Freixa X, Bellera N, Ortiz-Perez JT, et al. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J. 2012;33(1): 103-112.
14. Hahn JY, Song YB, Kim EK, et al. Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning onmyocardial reperfusion in patients with ST-segment elevationmyocardial infarction (POST) randomized trial. Circulation. 2013;128(17):1889-1896.
15. Eitel I, Stiermaier T, Rommel KP, et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevationmyocardial infarction: the randomized LIPSIA CONDITIONING trial. Eur Heart J. 2015;36 (44):3049-3057.
16. Hofsten DE, Kelbak H, Helqvist S, et al; DANAMI 3 Investigators. The Third Danish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treatment of culprit lesion only: rationale and design of the DANAMI 3 trial program. Am Heart J. 2015;169(5):613-621.
17. Kelbak H, Hofsten DE, Kober L, et al. Deferred versus conventional stent implantation in patients with ST-segment elevationmyocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. Lancet. 2016;387(10034):2199-2206.
18. Engstrom T, Kelbak H, Helqvist S, et al; DANAMI-3-PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386(9994):665-671.
19. World Medical Association. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. 2017. http://www.wma.net/en/30publications/10policies/b3/. Accessed February 8, 2017.
20. European Medicines Agency. European Guideline for Good Clinical Practice E6(R2). 2015. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/08/WC500191488.pdf. Accessed February 8, 2017.
21. Lonborg J, Vejlstrup N, Kelbak H, et al. Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevationmyocardial infarction predicts long-term clinical outcome: an observational study. Eur Heart J Cardiovasc Imaging. 2013;14(4):387-395.
22. Eitel I, de Waha S, Wohrle J, et al. Comprehensive prognosis assessment by CMR imaging after ST-segment elevationmyocardial infarction. J AmColl Cardiol. 2014;64(12):1217-1226.
23. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation. 2004;110(21): e506-e510.
24. Cohen MV, Yang XM, White J, Yellon DM, Bell RM, Downey JM. Cangrelor-mediated cardioprotection requires platelets and sphingosine phosphorylation. Cardiovasc Drugs Ther. 2016;30 (2):229-232.
25. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects themyocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res. 2004;95(3):230-232.
26. Manintveld OC, Te Lintel Hekkert M, van den Bos EJ, et al. Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol. 2007;292(3): H1551-H1560.
27. Zhou C, Yao Y, Zheng Z, et al. Stenting technique, gender, and age are associated with cardioprotection by ischaemic postconditioning in primary coronary intervention: a systematic review of 10 randomized trials. Eur Heart J. 2012;33(24): 3070-3077.
28. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation. 2008;117 (8):1037-1044.
29. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect onmyocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375(9716):727-734.
30. Lonborg J, Vejlstrup N, Kelbak H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevationmyocardial infarction. Eur Heart J. 2012;33(12):1491-1499.
31. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic "preconditioning" protects remote virginmyocardium from subsequent sustained coronary occlusion. Circulation. 1993;87(3):893-899.
32. White SK, Frohlich GM, Sado DM, et al. Remote ischemic conditioning reducesmyocardial infarct size and edema in patients with ST-segment elevationmyocardial infarction. JACC Cardiovasc Interv. 2015;8(1, pt B):178-188.
33. Hausenloy DJ, Kharbanda R, Rahbek Schmidt M, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevationmyocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J. 2015;36(29):1846-1848.
34. Ovize M, Baxter GF, Di Lisa F, et al;Working Group of Cellular Biology of Heart of European Society of Cardiology. Postconditioning and protection from reperfusion injury: where do we stand? position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2010;87(3): 406-423.
35. Lonborg J, Schoos MM, Kelbak H, et al. Impact of system delay on infarct size, myocardial salvage index, and left ventricular function in patients with ST-segment elevationmyocardial infarction. Am Heart J. 2012;164(4):538-546.